Neuralpulse is developing an implantable neuromodulation device that predicts and prevents seizures in patients with drug-resistant epilepsy. The system actively probes the brain to forecast impending seizures and delivers targeted stimulation to avert them, offering a proactive approach to seizure management.
Funding
Funding not disclosed
Founders
Product
Problem
Individuals with uncontrolled epilepsy face unpredictable seizures, significantly impacting their quality of life and requiring constant vigilance. Current neuromodulation therapies often lack the precision to anticipate and proactively avert seizure events.
Solution
Neuralpulse is developing an adaptive neuromodulation therapy designed to predict and prevent seizures in patients with drug-resistant epilepsy. The core of this technology is an implantable device that actively probes the brain with electrical pulses. By analyzing the brain's response to these probes, the system can forecast impending seizures. Subsequently, it delivers targeted therapeutic stimulation to avert the seizure before it occurs. This approach aims to provide a more proactive and effective seizure management solution compared to existing passive methods.
Target Audience
The primary target audience includes individuals diagnosed with uncontrolled epilepsy, particularly those with drug-resistant forms of the condition, and the neurosurgeons and neurologists who manage their care.
Features
- Implantable neuromodulation device for intracranial use.
- Active electrical probing of brain tissue to gather real-time neural response data.
- Proprietary algorithms for seizure prediction based on neural response patterns.
- Adaptive therapeutic stimulation delivery to prevent predicted seizures.
- Demonstrated safety and tolerability in first-in-human clinical studies.
- Enhanced seizure prediction accuracy compared to passive monitoring techniques.